Brian Thompson

“As John mentioned, specialty Rx is again largely contained to our Medicare Advantage book. And let me start with, I feel very adequately priced for how this will play out in 2025, despite the surprise here in the second half.”

“I'll lead with, I feel really good not only about how we finished the year in UnitedHealthcare 2023, growth at the top end of our ranges, performance run in positions across the board, but also as we step into the businesses for 2024, feel very good about the key assumptions that underpin our plan and am very…”

“Let me start with the trends that we’re seeing here in 2023 are as planned, overall medical and pharmacy. It’s really a good start to the year with our assumptions being validated as we kick off 2023.”

“Certainly as we look forward to 2022, the picture is a lot more clear than it has been over the past 20 months. I would say that we feel optimistic not only about our pricing and the rationality of the market, but most importantly the value that we're bringing to customers.”

“When I think about baseline, what I can say right now is, what we are seeing is largely tracking to our expectations. And as we had signaled, where we see abatement in services, it's largely offset by the increase in COVID-related costs.”